Protein kinases are pivotal regulators of cell signaling that modulate each other's functions and activities through site-specific phosphorylation events. These key regulatory modifications have not been studied comprehensively, because low cellular abundance of kinases has resulted in their underrepresentation in previous phosphoproteome studies. Here, we combine kinase-selective affinity purification with quantitative mass spectrometry to analyze the cell-cycle regulation of protein kinases. This proteomics approach enabled us to quantify 219 protein kinases from S and M phase-arrested human cancer cells. We identified more than 1000 phosphorylation sites on protein kinases. Intriguingly, half of all kinase phosphopeptides were upregulated in mitosis. Our data reveal numerous unknown M phase-induced phosphorylation sites on kinases with established mitotic functions. We also find potential phosphorylation networks involving many protein kinases not previously implicated in mitotic progression. These results provide a vastly extended knowledge base for functional studies on kinases and their regulation through site-specific phosphorylation.
We report a proteomics strategy to both identify and quantify cellular target protein interactions with externally introduced ligands. We determined dissociation constants for target proteins interacting with the ligand of interest by combining quantitative mass spectrometry with a defined set of affinity purification experiments. We demonstrate the general utility of this methodology in interaction studies involving small-molecule kinase inhibitors, a tyrosine-phosphorylated peptide and an antibody as affinity ligands.
Background and ObjectivesDarolutamide is a novel androgen receptor (AR) antagonist approved for the treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC). Accordingly, the drug–drug interaction (DDI) potential of darolutamide was investigated in both nonclinical and clinical studies.MethodsIn vitro studies were performed to determine the potential for darolutamide to be a substrate, inducer or inhibitor for cytochrome P450 (CYP) isoforms, other metabolizing enzymes and drug transporters. A phase I drug-interaction study in healthy volunteers evaluated the impact of co-administering rifampicin [CYP3A4 and P-glycoprotein (P-gp) inducer] and itraconazole [CYP3A4, P-gp and breast cancer resistance protein (BCRP) inhibitor] on the pharmacokinetics of darolutamide. Two further phase I studies assessed the impact of co-administering oral darolutamide on the pharmacokinetics of midazolam (sensitive CYP3A4 substrate) and dabigatran etexilate (P-gp substrate) and the impact on the pharmacokinetics of co-administered rosuvastatin [a substrate for BCRP, organic anion-transporting polypeptide (OATP)1B1, OATP1B3 and organic anion transporter (OAT)3].ResultsIn vitro, darolutamide was predominantly metabolized via oxidative biotransformation catalyzed by CYP3A4 and was identified as a substrate for P-gp and BCRP. The enzymatic activity of nine CYP isoforms was not inhibited or slightly inhibited in vitro with darolutamide, and a rank order and mechanistic static assessment indicated that risk of clinically relevant DDIs via CYP inhibition is very low. In vitro, darolutamide exhibited no relevant induction of CYP1A2 or CYP2B6 activity. Inhibition of BCRP-, P-gp-, OAT3-, MATE1-, MATE2-K-, OATP1B1- and OATP1B3-mediated transport was observed in vitro. Phase I data showed that darolutamide exposure increased 1.75-fold with co-administered itraconazole and decreased by 72% with rifampicin. Co-administration of darolutamide with CYP3A4/P-gp substrates showed no effect or only minor effects. Rosuvastatin exposure increased 5.2-fold with darolutamide because of BCRP and probably also OATPB1/OATPB3 inhibition.ConclusionsDarolutamide has a low potential for clinically relevant DDIs with drugs that are substrates for CYP or P-gp; increased exposure of BCRP and probably OATP substrates was the main interaction of note.Electronic supplementary materialThe online version of this article (10.1007/s13318-019-00577-5) contains supplementary material, which is available to authorized users.
An antibody-drug conjugate (ADC) is a unique therapeutic modality composed of a highly potent drug molecule conjugated to a monoclonal antibody. As the number of ADCs in various stages of nonclinical and clinical development has been increasing, pharmaceutical companies have been exploring diverse approaches to understanding the disposition of ADCs. To identify the key absorption, distribution, metabolism, and excretion (ADME) issues worth examining when developing an ADC and to find optimal scientifically based approaches to evaluate ADC ADME, the International Consortium for Innovation and Quality in Pharmaceutical Development launched an ADC ADME working group in early 2014. This white paper contains observations from the working group and provides an initial framework on issues and approaches to consider when evaluating the ADME of ADCs.
The P2X4 receptor is a ligand-gated ion channel that is expressed on a variety of cell types, especially those involved in inflammatory and immune processes. High-throughput screening led to a new class of P2X4 inhibitors with substantial CYP 3A4 induction in human hepatocytes. A structure-guided optimization with respect to decreased pregnane X receptor (PXR) binding was started. It was found that the introduction of larger and more polar substituents on the ether linker led to less PXR binding while maintaining the P2X4 inhibitory potency. This translated into significantly reduced CYP 3A4 induction for compounds 71 and 73. Unfortunately, the in vivo pharmacokinetic (PK) profiles of these compounds were insufficient for the desired profile in humans. However, BAY-1797 (10) was identified and characterized as a potent and selective P2X4 antagonist. This compound is suitable for in vivo studies in rodents, and the antiinflammatory and anti-nociceptive effects of BAY-1797 were demonstrated in a mouse complete Freund's adjuvant (CFA) inflammatory pain model.
Cytochrome P450s (CYPs), a superfamily
of enzymes, are involved
in the biotransformation of endogenous and xenobiotic chemicals and
mainly responsible for the metabolic clearance of widely prescribed
drugs. Out of the 57 human isoforms, only a few, most notably CYP3A4,
are considered to be important in this process. CYP1A1, one of the
three isoforms of the CYP1 family, is widely believed to play an important
role in the metabolism and activation of numerous procarcinogens,
e.g., polyaromatic hydrocarbons (PAHs) or aromatic amines. It is also
known that CYP1A1 is highly inducible by endogenous and exogenous
factors, e.g., PAHs. However, CYP1A1 has not been considered to play
a significant role in the metabolic clearance of drugs, since this
isoform has been detected only in extrahepatic tissues in small amounts.
In contrast to conventional wisdom, we herein demonstrate the expression
of CYP1A1 protein in human liver microsomal preparations. The expression
levels of CYP1A1 were quantified by Western blot and LC/MS analyses
and corresponded well with enzymatic activities of highly selective
CYP1A1 reactions. In a panel of 29 individual liver microsomal preparations,
highly variable and substantial expression levels (up to ∼10
pmol/mg) were measured. Together with the high selectivity and especially
the high metabolic efficiency of CYP1A1 shown for granisetron and
riociguat, it is demonstrated that CYP1A1 plays an important role
in the metabolic clearance of these drugs and is responsible for the
clinically observed interindividual variability in their pharmacokinetics.
Therefore, the importance of CYP1A1 in drug discovery and development
needs to be reconsidered.
Idiopathic
pulmonary fibrosis (IPF) is a rare and devastating chronic
lung disease of unknown etiology. Despite the approved treatment options
nintedanib and pirfenidone, the medical need for a safe and well-tolerated
antifibrotic treatment of IPF remains high. The human prostaglandin
F receptor (hFP-R) is widely expressed in the lung tissue and constitutes
an attractive target for the treatment of fibrotic lung diseases.
Herein, we present our research toward novel quinoline-based hFP-R
antagonists, including synthesis and detailed structure–activity
relationship (SAR). Starting from a high-throughput screening (HTS)
hit of our corporate compound library, multiple parameter improvementsincluding
increase of the relative oral bioavailability F
rel from 3 to ≥100%led to a highly potent and
selective hFP-R antagonist with complete oral absorption from suspension. BAY-6672 (46) representsto the best of
our knowledgethe first reported FP-R antagonist to demonstrate in vivo efficacy in a preclinical animal model of lung fibrosis,
thus paving the way for a new treatment option in IPF.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.